(Q44180518)

30 November 2017

title

Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum (English)

1 reference

30 November 2017

Claudia Lanvers

1

1 reference

30 November 2017

Joao Paulo Vieira Pinheiro

2

1 reference

30 November 2017

Georg Hempel

3

1 reference

30 November 2017

Gudrun Wuerthwein

4

1 reference

30 November 2017

Joachim Boos

5

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

30 November 2017

published in

Analytical Biochemistry

1 reference

30 November 2017

volume

309

1 reference

30 November 2017

issue

1

1 reference

30 November 2017

page(s)

117-126

1 reference

Use of ?-asparaginase in childhood ALL

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

L-asparaginase and PEG asparaginase--past, present, and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

Comparative pharmacokinetic studies of three asparaginase preparations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

Increased antithrombin III concentration in children with acute lymphatic leukaemia receiving L-asparaginase therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

Changes in coagulation and fibrinolysis in childhood acute lymphoblastic leukaemia re-induction therapy using three different asparaginase preparations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

L-Asparaginase and L-Asparagine Metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

A fluorometric assay for L-asparaginase activity and monitoring of L-asparaginase therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

Site-specific mutagenesis of Escherichia coli asparaginase II. None of the three histidine residues is required for catalysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

Factors influencing the "in vitro" enhancement of L-asparaginase activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

The influence of human serum on the anti-tumour activity of two L-asparaginases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

Antitumor activity of L-asparaginase from Thermus thermophilus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

Structural basis for the activity and substrate specificity of Erwinia chrysanthemi L-asparaginase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

A simple and rapid method for the estimation of l-asparaginase in chromatographic and electrophoretic effluents: Comparison with other methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-2697%2802%2900232-4

10.1016/S0003-2697(02)00232-4

7 January 2021

Identifiers

DOI

1 reference

30 November 2017

1 reference